Uploaded August 2025 | Updated September 2026, 2 weeks ago
Tags: CBG, Cannabigerol, Cannabinoids, THC, Tetrahydrocannabinol, Hemp-Products
Dr. Dustin Sulak, Co-Founder of Healer.com @Healercom, presents “Bridging the Gap: New Findings on the Utility of CBG-Dominant and THC-Containing Hemp Products” at CannMed 2025.
Background: In many jurisdictions, medical cannabis programs present challenges for businesses and patients alike, including onerous regulations, advertising and financial censorship, and other marketplace disadvantages. As the medical cannabis industry struggles to adapt among a patchwork of regulatory environments, the nutritional supplement sector of the hemp market continues to grow while enjoying advantages like interstate commerce and the use of conventional payment methods. Hemp customers also benefit from a more competitive and free marketplace. Novel hemp-derived product classes have emerged to meet consumers’ needs, including Cannabigerol (CBG)-dominant formulations and 2018 Farm Bill-compliant THC-containing edibles. These hemp products offer potentially-therapeutic effects for people with conditions for which cannabis is commonly used, including chronic pain and anxiety, may provide therapeutic benefits for individuals who have not responded favorably to the more commonly available CBD-dominant hemp products, and may enable greater access to the therapeutic effects of clinically-relevant doses of THC.
CBG is becoming increasingly popular among consumers, yet we still have very little human clinical evidence that characterize its therapeutic effects, adverse effects, effective dosages, and typical use patterns. With preclinical studies suggesting substantial a therapeutic potential in several conditions, more human data on CBG-dominant products is needed. Additionally, increasing clinical data demonstrate substantial benefits of therapeutic cannabis use for people with dementia; the potential to achieve similar results with hemp products
remains largely unexplored.
Objective: We aimed to evaluate the reasons for use, usage patterns, therapeutic effects, adverse effects, and qualitative reports of two populations of consumers, one using CBG- dominant and another using THC-containing hemp products, both with well-characterized compositions and dosing formats amenable to reporting specific dosages.
0:00 - The Unintended Consequences of Central Control
1:33 - Healer's Approach: Using the Farm Bill for New Products
3:17 - The Mechanisms of Action for CBG
6:20 - A Review of Existing CBG Clinical Data
7:26 - Healer's CBG Customer Survey Methodology
8:55 - Survey Results: Efficacy for Pain, Anxiety, and Sleep
11:00 - Summary of CBG Findings and the Role of CBG
17:56 - Bridging the Gap: Cannabis and Dementia
19:15 - A Clinical Study on Agitation in Dementia Patients
20:36 - The Dangers of Conventional Dementia Treatments
22:57 - Introducing the Respite Gummy for Dementia
24:37 - Promising Results from Early Respite Gummy Users
26:15 - Insights from the Nursing Hotline
30:35 - A Patient's Story: The Power of Cannabis
32:15 - Conclusion
Learn More about CannMed: cannmedevents.com
Sign Up for Our Newsletter: share.hsforms.com/1oi57oJDnRN-Uqqc9YPByRA20xr2
The CannMed 25 Innovation & Investment Summit showcased its first international venue, the Wyndham Grand Rio Mar Golf & Beach Resort in Puerto Rico from June 17 - 20, 2025. Since its inception at Harvard Medical School in 2016, CannMed has earned a reputation as the premier destination for cutting-edge research, emerging technologies, and investment opportunities. CannMed 25 continues this tradition with medicinal plant researchers, clinicians and venture capitalists who view this Summit as the industry’s number one showcase for the latest advances in plant-based science, medicine, cultivation, and safety.
Tags: CBG, Cannabigerol, Cannabinoids, THC, Tetrahydrocannabinol, Hemp-Products
Dr. Dustin Sulak, Co-Founder of Healer.com @Healercom, presents “Bridging the Gap: New Findings on the Utility of CBG-Dominant and THC-Containing Hemp Products” at CannMed 2025.
Background: In many jurisdictions, medical cannabis programs present challenges for businesses and patients alike, including onerous regulations, advertising and financial censorship, and other marketplace disadvantages. As the medical cannabis industry struggles to adapt among a patchwork of regulatory environments, the nutritional supplement sector of the hemp market continues to grow while enjoying advantages like interstate commerce and the use of conventional payment methods. Hemp customers also benefit from a more competitive and free marketplace. Novel hemp-derived product classes have emerged to meet consumers’ needs, including Cannabigerol (CBG)-dominant formulations and 2018 Farm Bill-compliant THC-containing edibles. These hemp products offer potentially-therapeutic effects for people with conditions for which cannabis is commonly used, including chronic pain and anxiety, may provide therapeutic benefits for individuals who have not responded favorably to the more commonly available CBD-dominant hemp products, and may enable greater access to the therapeutic effects of clinically-relevant doses of THC.
CBG is becoming increasingly popular among consumers, yet we still have very little human clinical evidence that characterize its therapeutic effects, adverse effects, effective dosages, and typical use patterns. With preclinical studies suggesting substantial a therapeutic potential in several conditions, more human data on CBG-dominant products is needed. Additionally, increasing clinical data demonstrate substantial benefits of therapeutic cannabis use for people with dementia; the potential to achieve similar results with hemp products
remains largely unexplored.
Objective: We aimed to evaluate the reasons for use, usage patterns, therapeutic effects, adverse effects, and qualitative reports of two populations of consumers, one using CBG- dominant and another using THC-containing hemp products, both with well-characterized compositions and dosing formats amenable to reporting specific dosages.
0:00 - The Unintended Consequences of Central Control
1:33 - Healer's Approach: Using the Farm Bill for New Products
3:17 - The Mechanisms of Action for CBG
6:20 - A Review of Existing CBG Clinical Data
7:26 - Healer's CBG Customer Survey Methodology
8:55 - Survey Results: Efficacy for Pain, Anxiety, and Sleep
11:00 - Summary of CBG Findings and the Role of CBG
17:56 - Bridging the Gap: Cannabis and Dementia
19:15 - A Clinical Study on Agitation in Dementia Patients
20:36 - The Dangers of Conventional Dementia Treatments
22:57 - Introducing the Respite Gummy for Dementia
24:37 - Promising Results from Early Respite Gummy Users
26:15 - Insights from the Nursing Hotline
30:35 - A Patient's Story: The Power of Cannabis
32:15 - Conclusion
Learn More about CannMed: cannmedevents.com
Sign Up for Our Newsletter: share.hsforms.com/1oi57oJDnRN-Uqqc9YPByRA20xr2
The CannMed 25 Innovation & Investment Summit showcased its first international venue, the Wyndham Grand Rio Mar Golf & Beach Resort in Puerto Rico from June 17 - 20, 2025. Since its inception at Harvard Medical School in 2016, CannMed has earned a reputation as the premier destination for cutting-edge research, emerging technologies, and investment opportunities. CannMed 25 continues this tradition with medicinal plant researchers, clinicians and venture capitalists who view this Summit as the industry’s number one showcase for the latest advances in plant-based science, medicine, cultivation, and safety.
